Park National Corp OH lowered its position in shares of Johnson & Johnson (NYSE: JNJ – Get Rating) by 1.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 287,233 shares of the company stock after selling 4,944 shares during the quarter. Johnson & Johnson accounts for about 2.1% of Park National Corp OH’s holdings, making the stock its 8th largest position. Park National Corp OH’s holdings in Johnson & Johnson were worth $ 50,906,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. raised its holdings in shares of Johnson & Johnson by 2.6% during the fourth quarter. BlackRock Inc. now owns 200,021,352 shares of the company stock valued at $ 34,217,654,000 after acquiring an additional 4,982,885 shares during the period. State Street Corp increased its stake in Johnson & Johnson by 1.8% in the 4th quarter. State Street Corp now owns 144,677,639 shares of the company stock valued at $ 24,750,004,000 after buying an additional 2,492,359 shares during the period. Geode Capital Management LLC increased its stake in Johnson & Johnson by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 44,405,610 shares of the company stock valued at $ 7,576,867,000 after buying an additional 1,084,834 shares during the period. Morgan Stanley increased its stake in Johnson & Johnson by 3.1% in the 2nd quarter. Morgan Stanley now owns 25,066,744 shares of the company stock valued at $ 4,129,496,000 after buying an additional 760,796 shares during the period. Finally, Norges Bank acquired a new position in Johnson & Johnson in the 4th quarter valued at approximately $ 4,172,929,000. Institutional investors and hedge funds own 68.78% of the company stock.
In other news, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction on Friday, June 10th. The shares were sold at an average price of $ 173.00, for a total value of $ 6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares in the company, valued at approximately $ 12,336,803. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider William Hait sold 29,699 shares of the stock in a transaction on Thursday, April 21st. The shares were sold at an average price of $ 183.58, for a total transaction of $ 5,452,142.42. Following the completion of the transaction, the insider now owns 80,236 shares of the company stock, valued at approximately $ 14,729,724.88. The disclosure for this sale can be found here. Over the last three months, insiders sold 78,161 shares of company stock valued at $ 13,895,302. Insiders own 0.35% of the company stock.
Several research analysts have weighed in on JNJ shares. Sanford C. Bernstein lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and upped their price target for the company from $ 180.00 to $ 183.00 in a research note on Wednesday, March 16th. Morgan Stanley dropped their price objective on shares of Johnson & Johnson from $ 175.00 to $ 173.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 6th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 17th. Raymond James increased their price target on shares of Johnson & Johnson from $ 195.00 to $ 196.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 20th. Finally, Citigroup dropped their price target on shares of Johnson & Johnson from $ 210.00 to $ 205.00 in a research note on Tuesday, May 17th. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $ 190.50.
NYSE JNJ opened at $ 169.46 on Monday. The company has a current ratio of 1.39, a quick ratio of 1.14 and a debt-to-equity ratio of 0.39. The company has a fifty day simple moving average of $ 178.10 and a 200 day simple moving average of $ 173.00. The company has a market cap of $ 445.92 billion, a P / E ratio of 22.84, a P / E / G ratio of 3.35 and a beta of 0.66. Johnson & Johnson has a 1 year low of $ 155.72 and a 1 year high of $ 186.69.
Johnson & Johnson (NYSE: JNJ – Get Rating) last posted its quarterly earnings data on Tuesday, April 19th. The company reported $ 2.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $ 2.60 by $ 0.07. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The business had revenue of $ 23.43 billion during the quarter, compared to the estimate consensus of $ 23.62 billion. During the same period in the prior year, the firm earned $ 2.59 EPS. Johnson & Johnson’s quarterly revenue was up 5.0% compared to the same quarter last year. Equities research analysts forecast that Johnson & Johnson will post 10.23 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th were issued a $ 1.13 dividend. The ex-dividend date was Monday, May 23rd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $ 1.06. This represents a $ 4.52 dividend on an annualized basis and a yield of 2.67%. Johnson & Johnson’s dividend payout ratio is 60.92%.
Johnson & Johnson Company Profile: (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health / beauty products under the AVEENO, CLEAN & CLEAR, DR.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE: JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.